Literature DB >> 18435429

Globally optimal trial design for local decision making.

Simon Eckermann1, Andrew R Willan.   

Abstract

Value of information methods allows decision makers to identify efficient trial design following a principle of maximizing the expected value to decision makers of information from potential trial designs relative to their expected cost. However, in health technology assessment (HTA) the restrictive assumption has been made that, prospectively, there is only expected value of sample information from research commissioned within jurisdiction. This paper extends the framework for optimal trial design and decision making within jurisdiction to allow for optimal trial design across jurisdictions. This is illustrated in identifying an optimal trial design for decision making across the US, the UK and Australia for early versus late external cephalic version for pregnant women presenting in the breech position. The expected net gain from locally optimal trial designs of US$0.72M is shown to increase to US$1.14M with a globally optimal trial design. In general, the proposed method of globally optimal trial design improves on optimal trial design within jurisdictions by: (i) reflecting the global value of non-rival information; (ii) allowing optimal allocation of trial sample across jurisdictions; (iii) avoiding market failure associated with free-rider effects, sub-optimal spreading of fixed costs and heterogeneity of trial information with multiple trials. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 18435429     DOI: 10.1002/hec.1353

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  19 in total

Review 1.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  The value of value of information: best informing research design and prioritization using current methods.

Authors:  Simon Eckermann; Jon Karnon; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography.

Authors:  Paolo Pertile
Journal:  Int J Health Care Finance Econ       Date:  2009-01-18

4.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

Review 5.  Should financial incentives be used to differentially reward 'me-too' and innovative drugs?

Authors:  Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

8.  A practical guide to value of information analysis.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2015-02       Impact factor: 4.981

Review 9.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 10.  Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.